University of Minnesota Medical School Jun 11 2026 New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection. The study, published in Clinical Infectious Diseases and co-led by a University of Minnesota Medical School research team, evaluated

Tag-uri: Coronavirus